focus -WSS

focus

author：fashion 2025-09-29 22:47:31 - browse：5

The FDA building -- First Opinion coverage from STAT — Adobe

The clearance of a first-of-its-kind cancer treatment made by Amgen is on shakier ground following a Food and Drug Administration advisory committee meeting Thursday.

Regulatory advisers voted 10-2 that the data on the company’s drug Lumakras, a treatment for lung cancer, could not be properly assessed. Lumakras targets a specific mutation to a protein called KRAS, which is one of the most common genetic mutations in cancer.

The vote comes as Amgen is hoping to convert a conditional approval for the drug to a full approval based on a 345-person study called CodeBreaK 200, in which Lumakras met the primary endpoint, delaying tumor growth approximately five weeks longer than the standard of care medication, docetaxel. The drug didn’t extend patients’ overall survival.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Readout Newsletter: Illumina, CRISPR, Regeneron

hotspot

explore

WSS

Study finds gene variants tied to breast cancer risk in Black women

This gene therapy has record $4.25 million price. It's saved children.

Adam's Take: Intra

Pfizer, Moderna say biotech, pharma drug development is a sprint

Reports of telehealth's death have been greatly exaggerated

Pregnancy ages women, but effects reverse after delivery

focus

focus

entertainment

Sports medicine is finally prioritizing gender equality

Making the case for fair compensation in clinical trials

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Biogen joins immunology wave with $1.15 billion acquisition of HI

Virginia high school admissions case could be legal follow

ASCO eve: Let’s set the table for this year's meeting

Guidelines to prevent youth baseball injuries need more muscle

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Chinese researcher claims birth of first gene

knowledge

Bird flu surveillance in wastewater gets boost from consortium

Cue Health, Covid

Making the case for fair compensation in clinical trials

Investigation reveals sickle cell patients pressured into sterilizations

Erich Jarvis studies song birds to learn about human stuttering

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

explore

hotspot

explore

focus